Pacira BioSciences Reports Three-Year Data Showing Sustained Efficacy of PCRX-201 Gene Therapy for Knee Osteoarthritis
Reuters
Oct 28
Pacira BioSciences Reports Three-Year Data Showing Sustained Efficacy of PCRX-201 Gene Therapy for Knee Osteoarthritis
Pacira BioSciences Inc. announced updated three-year results from an open-label Phase 1 clinical trial evaluating PCRX-201 (enekinragene inzadenovec), a novel gene therapy candidate for osteoarthritis of the knee. The data, which have already been presented, demonstrate that a single intra-articular injection of PCRX-201 was well tolerated and produced sustained clinical improvements in pain, stiffness, and function for up to 156 weeks across all patient subgroups and disease severities. PCRX-201 utilizes a high-capacity adenovirus gene therapy vector to increase production of interleukin-1 receptor antagonist (IL-1Ra), aiming to reduce chronic inflammation in the knee joint. The results support Pacira's ongoing Phase 2 study strategy. In March 2024, PCRX-201 received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9562193-en) on October 28, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.